• 1^er thème : Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

[pdf]F -Barlesi_Lux-Lung 1_ 2012[/pdf]

[pdf]LUX LUNG 1 _Miller Hirsch Cadranel.pdf

 

• 2^nd thème : Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

[pdf]M Pérol-Titan _GFPC 2012[/pdf]

[pdf]TITAN[/pdf]